Sun Pharma Share Price Target 2025, 2030, 2040, 2050
One of India’s leading pharmaceutical businesses, Sun Pharmaceutical Industries Ltd., makes specialized generic drugs worldwide. Many investors are intrigued by Sun Pharma future share price goals.
This article will examine Sun Pharma fundamentals, expert projections, and share price estimates for 2024, 2025, 2030, 2040, and 2050.
What is Sun Pharmaceutical Industries Ltd NSE: SUNPHARMA?
Sun Pharmaceutical Industries Ltd., located in Mumbai, India, trades as SUNPHARMA on the India National Stock Exchange. Sun Pharma, founded in 1983, is India’s biggest pharmaceutical firm in market valuation and revenue. Generic, over-the-counter, anti-retroviral, and API medications are its specialties.
Fundamental Table
| Metric | Value |
| Market Cap | ₹446,520 crore |
| P/E Ratio | 42.49 |
| EPS | ₹43.45 |
| Dividend Yield | 0.73% |
| ROCE | 15.04% |
| ROE | 15.04% |
| Debt to Equity | 0.04 |
Key Metrics Table
| Metric | Value |
| 52 Week High | ₹1,873.35 |
| 52 Week Low | ₹1,068.35 |
| Book Value per Share | ₹265.49 |
| Price to Book Value | 7.03 |
| Free Float | 45.52% |
| Promoter Holding | 54.48% |
Peers & Comparison Table
| Company | Market Cap (₹ Cr) | P/E Ratio | ROE (%) |
| Sun Pharma | 446,520 | 42.49 | 15.04 |
| Dr Reddy | 109,319 | 19.64 | 19.74 |
| Cipla | 132,332 | 30.75 | 15.43 |
| Lupin | 48,660 | 42.41 | 7.35 |
| Aurobindo Pharma | 45,328 | 20.44 | 9.73 |
Sun Pharma share price Target Tomorrow
| Price Type | Change |
| Maximum | +15.48 |
| Minimum | -10.68 |
Sun Pharma share price Target 2025
Sun Pharma could profit from its robust product pipeline and growing penetration in developing countries in 2025. The company’s biosimilar and specialized product expenditures should pay off, raising share prices. In 2025, its share price target would be ₹2162, as per our analysis.
By our prediction, its share price would be between ₹1366 and ₹2162 in 2025.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2025 | 1366 | 2162 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
| January | 1693 | 1902 |
| February | 1568 | 1789 |
| March | 1510 | 1795 |
| April | 1472 | 1808 |
| May | 1428 | 1824 |
| June | 1366 | 1845 |
| July | 1411 | 1887 |
| August | 1578 | 1925 |
| September | 1590 | 1958 |
| October | 1630 | 1987 |
| November | 1725 | 2022 |
| December | 1845 | 2162 |
share price Target 2030
Sun Pharma to be a worldwide pharmaceutical leader by 2030. Long-term R&D, smart acquisitions, and high-value market emphasis could boost growth. We predict Sun Pharma share price to reach between ₹3,500 and ₹4,500 by 2030.
| Year | Minimum Price (₹) | Maximum Price (₹) |
| 2030 | 3,500 | 4,500 |
| Month | Minimum Price (₹) | Maximum Price (₹) |
| January | 3,500 | 3,600 |
| February | 3,550 | 3,650 |
| March | 3,600 | 3,700 |
| April | 3,650 | 3,750 |
| May | 3,700 | 3,800 |
| June | 3,750 | 3,850 |
| July | 3,800 | 3,900 |
| August | 3,850 | 3,950 |
| September | 3,900 | 4,000 |
| October | 3,950 | 4,100 |
| November | 4,000 | 4,300 |
| December | 4,200 | 4,500 |
Share Price Target 2050
Projecting 2050 share values requires conjecture owing to the lengthy time horizon. We can predict a range if Sun Pharma continues its growth track and reacts to market changes. Sun Pharma might become a worldwide pharmaceutical giant by 2050, with a share price between ₹10,000 and ₹15,000.
| Year | Minimum Price (₹) | Maximum Price (₹) |
| 2050 | 10,000 | 15,000 |
| Month | Minimum Price (₹) | Maximum Price (₹) |
| January | 10,000 | 10,500 |
| February | 10,200 | 10,700 |
| March | 10,400 | 10,900 |
| April | 10,600 | 11,100 |
| May | 10,800 | 11,300 |
| June | 11,000 | 11,500 |
| July | 11,200 | 11,700 |
| August | 11,400 | 11,900 |
| September | 11,600 | 12,100 |
| October | 11,800 | 12,500 |
| November | 12,000 | 13,000 |
| December | 12,500 | 15,000 |
Should I buy Sun Pharma stock?
| Year | Minimum Price (₹) | Maximum Price (₹) |
| 2025 | 1366 | 2162 |
| 2030 | 3,500 | 4,500 |
| 2050 | 10,000 | 15,000 |
Many considerations must be considered while buying Sun Pharma shares. The company market position, product pipeline, and worldwide presence might boost growth. Investors should also consider regulatory issues, price concerns, and pharmaceutical industry competitiveness. Before investing, investigate and analyze your financial objectives.
Sun Pharmaceutical Industries Ltd earning results
Sun Pharma has consistently performed financially. Recent quarterly performance summary:
| Quarter | Revenue (₹ Cr) | Net Profit (₹ Cr) | EPS (₹) |
| Q2 FY24 | 12,192 | 2,375 | 9.91 |
| Q1 FY24 | 11,519 | 2,061 | 8.60 |
| Q4 FY23 | 10,844 | 1,984 | 8.28 |
| Q3 FY23 | 11,241 | 2,166 | 9.04 |
Expert forecasts on the future of Sun Pharmaceutical Industries Ltd.
Industry analysts are optimistic about Sun Pharma future. Many analysts expect the company specialist product emphasis, R&D spending, and developing market development to generate long-term growth. Important expert projections include:
- Continued specialized expansion, especially dermatology and ophthalmology.
- Market share growth in the US, India, and developing markets.
- Cost reductions and product mix improvements may boost margins.
- Patent cliffs for some branded medications provide biosimilar and complicated generic opportunities.
- Possible strategic acquisitions to boost product and market share.
Is Sun Pharma stock good to buy? (bull case & bear case)
Bull Case:
- Strong Indian market position and expanding worldwide exposure
- Strong specialized and complicated generic pipeline
- Continuous R&D investment for innovation and growth
- Strong financial sheet, minimal debt
- Operational efficiency and product mix may boost margins.
Bear Case:
- Regulatory concerns in important markets, including US FDA inspection
- Increased generic drug competition causes price pressures
- International revenue changes due to currency volatility
- Depending on a few core goods for most revenue
- Possible integration issues from future purchases
Conclusion
Sun Pharmaceutical Industries Ltd. is a worldwide pharmaceutical leader. With its strong market position, concentration on specialist goods, and smart R&D expenditures, the firm is poised for development. This article’s share price projections are based on current trends and expert analysis, but investors should remember that the stock market is unpredictable and vulnerable to internal and external influences. Before investing, you must study, assess your risk tolerance, and contact a financial expert.
FAQs
Sun Pharma develops, manufactures, and sells generic drugs and APIs.
Since 2020, Sun Pharma stock has appreciated due to its concentration on specialist goods and worldwide growth.
Specialty product expansion, emerging market market share increase, and complicated generics and biosimilar R&D are growth drivers.
Sun Pharma is India’s biggest pharmaceutical firm by market valuation and has a worldwide reach to rival its rivals.
Regulatory difficulties, generic medicine price pressures, currency changes, and acquisition integration concerns are major hazards.
